Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 7, 2014 - Issue 3
Submit an article Journal homepage
509
Views
5
CrossRef citations to date
0
Altmetric
Drug Profiles

Empagliflozin for the treatment of Type 2 diabetes

Muralikrishna Gangadharan KomalaRenal Research Lab, Kolling Institute of Medical Research, Sydney University, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065, Australia
&
Amanda MatherRenal Research Lab, Kolling Institute of Medical Research, Sydney University, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065, AustraliaCorrespondence[email protected]
Pages 271-279 | Published online: 09 Apr 2014

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Wenjing Wang, Na Gan, Qiaomei Sun, Di Wu, Ludan Zhao, Zili Suo, Peixiao Tang & Hui Li. (2020) Binding properties of sodium glucose co-transporter-2 inhibitor empagliflozin to human serum albumin: spectroscopic methods and computer simulations. Journal of Biomolecular Structure and Dynamics 38:11, pages 3178-3187.
Read now
Lakshini Y Herat, Vance B Matthews, Aaron L Magno, Marcio G Kiuchi, Revathy Carnagarin & Markus P Schlaich. (2020) An evaluation of empagliflozin and it’s applicability to hypertension as a therapeutic option. Expert Opinion on Pharmacotherapy 21:10, pages 1157-1166.
Read now
R. Devi, Ghanshyam Mali, Indrani Chakraborty, Mazhuvancherry Kesavan Unnikrishnan & Suhaj Abdulsalim. (2017) Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Postgraduate Medicine 129:3, pages 382-392.
Read now
Michael A Nauck. (2014) Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Design, Development and Therapy 8, pages 1380-1380.
Read now

Articles from other publishers (1)

Deborah Hinnen. (2015) Short commentary on empagliflozin and its potential clinical impact. Therapeutic Advances in Endocrinology and Metabolism 6:2, pages 68-81.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.